January 3, 2017 09:33 AM EST

Medigene spins out AAV tech to a new biotech upstart in Sweden

Arsalan Arif

Founder

Germany’s Medigene AG is getting a new biotech startup going, out-licensing its AAV-like particle tech to the newly minted Swedish biotech company 2A Pharma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Medigene spins out AAV tech to a new biotech upstart in Sweden

Arsalan Arif

Founder

Sign up to read this article for free.

A look at biotech's year of the megaround

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Medi­gene spins out AAV tech to a new biotech up­start in Swe­den

Arsalan Arif

Founder

Sign up to read this article for free.

more like this

A look at biotech's year of the megaround

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Medigene spins out AAV tech to a new biotech upstart in Sweden

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts